Q2 Earnings Forecast for Veracyte Issued By Leerink Partnrs

Veracyte, Inc. (NASDAQ:VCYT) – Stock analysts at Leerink Partnrs lowered their Q2 2025 earnings estimates for Veracyte in a report issued on Monday, April 21st. Leerink Partnrs analyst P. Souda now anticipates that the biotechnology company will earn $0.24 per share for the quarter, down from their prior forecast of $0.26. The consensus estimate for Veracyte’s current full-year earnings is $0.68 per share. Leerink Partnrs also issued estimates for Veracyte’s Q4 2025 earnings at $0.23 EPS and FY2025 earnings at $0.78 EPS.

Several other research firms have also recently issued reports on VCYT. Guggenheim reduced their price objective on shares of Veracyte from $45.00 to $37.00 and set a “buy” rating on the stock in a research report on Wednesday, April 9th. Needham & Company LLC reiterated a “buy” rating and issued a $51.00 price target on shares of Veracyte in a report on Tuesday, February 25th. Stephens reissued an “overweight” rating and set a $45.00 price objective on shares of Veracyte in a report on Wednesday, March 26th. UBS Group lifted their target price on Veracyte from $46.00 to $49.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th. Finally, StockNews.com downgraded Veracyte from a “buy” rating to a “hold” rating in a research report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.60.

Veracyte Trading Up 1.7 %

NASDAQ VCYT opened at $31.13 on Wednesday. Veracyte has a 12 month low of $19.09 and a 12 month high of $47.32. The stock has a market cap of $2.43 billion, a PE ratio of -207.53 and a beta of 2.03. The stock’s 50 day moving average is $32.79 and its 200 day moving average is $37.35.

Veracyte (NASDAQ:VCYT) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.29 by $0.07. Veracyte had a positive return on equity of 3.02% and a negative net margin of 2.18%. The business had revenue of $118.63 million for the quarter, compared to analysts’ expectations of $110.73 million. During the same period last year, the firm earned ($0.39) earnings per share.

Institutional Trading of Veracyte

A number of institutional investors have recently bought and sold shares of the stock. Ieq Capital LLC bought a new stake in shares of Veracyte in the 4th quarter worth about $580,000. Barclays PLC raised its position in Veracyte by 138.6% in the 3rd quarter. Barclays PLC now owns 146,402 shares of the biotechnology company’s stock worth $4,983,000 after purchasing an additional 85,033 shares during the period. Jennison Associates LLC lifted its stake in Veracyte by 116.3% in the fourth quarter. Jennison Associates LLC now owns 833,754 shares of the biotechnology company’s stock worth $33,017,000 after purchasing an additional 448,251 shares during the last quarter. KBC Group NV lifted its stake in Veracyte by 44.6% in the fourth quarter. KBC Group NV now owns 3,872 shares of the biotechnology company’s stock worth $153,000 after purchasing an additional 1,195 shares during the last quarter. Finally, Proficio Capital Partners LLC purchased a new position in shares of Veracyte during the fourth quarter valued at approximately $1,179,000.

About Veracyte

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.